Cytophage Technologies Balance Sheet

Financials in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	1.52	0.03	2.25
Short-Term Investments	-	0.01	-
Cash & Short-Term Investments	1.52	0.04	2.25
Cash Growth	3357.36%	-98.04%	-
Other Receivables	0.2	0.34	0.46
Receivables	0.2	0.34	0.46
Prepaid Expenses	0.1	0.01	-
Restricted Cash	-	2.46	-
Other Current Assets	-	0.1	0.05
Total Current Assets	1.82	2.95	2.75
Property, Plant & Equipment	3.11	2.49	0.94
Total Assets	4.94	5.44	3.69
Accounts Payable	0.47	0.36	0.11
Accrued Expenses	-	0.41	0.02
Short-Term Debt	-	0.03	-
Current Portion of Leases	0.22	0.35	0.11
Other Current Liabilities	-	2.5	-
Total Current Liabilities	0.68	3.64	0.24
Long-Term Leases	1.32	1.43	-
Total Liabilities	2.01	5.07	0.24
Common Stock	25.28	16.18	15.44
Retained Earnings	-26.56	-19.09	-14.45
Comprehensive Income & Other	4.21	3.28	2.46
Shareholders' Equity	2.93	0.37	3.45
Total Liabilities & Equity	4.94	5.44	3.69
Total Debt	1.54	1.8	0.11
Net Cash (Debt)	-0.02	-1.76	2.14
Net Cash Per Share	-0.00	-0.04	0.05
Filing Date Shares Outstanding	53.94	42.81	40.93
Total Common Shares Outstanding	53.94	42.81	40.93
Working Capital	1.14	-0.69	2.52
Book Value Per Share	0.05	0.01	0.08
Tangible Book Value	2.93	0.37	3.45
Tangible Book Value Per Share	0.05	0.01	0.08
Machinery	-	1.26	1.15
Leasehold Improvements	-	0.05	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.